echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jiangsu's second centralized procurement saw the highest drop of 94%, and the consumables market welcomes the "big test" of price cuts

    Jiangsu's second centralized procurement saw the highest drop of 94%, and the consumables market welcomes the "big test" of price cuts

    • Last Update: 2021-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical News, June 18, June 15, Jiangsu Medical Insurance Bureau released the latest developments, Jiangsu Province has completed the fifth round of centralized procurement negotiations for medical consumables
    .
     
    It is understood that since Jiangsu took the lead in the procurement of coronary stent belts in 2019, it has successively carried out 5 rounds of medical consumables belt procurement, involving a total of 2,426 products in cardiovascular, ophthalmology, orthopedics, general surgery and other departments, an average decrease of 54%.

    .
     
    Five rounds of medical consumables and tape purchase decline in Jiangsu Province
     
    This round of centralized procurement involves 5 types of medical consumables, including intraocular lenses, coronary dilatation balloons, dual-chamber pacemakers, coronary guide wires, and coronary guide catheters
    .
    Among them, intraocular lenses, coronary balloons, and pacemakers have experienced the baptism of centralized procurement in Jiangsu Province in 2019
    .
    From the perspective of price reduction, the decline of "secondary centralized procurement" products has increased significantly, and the highest decline of coronary balloons is as high as 94%
    .
     
    Coronary interventional products "all in one catch"
     
    With the implementation of the results of the national procurement of coronary stents, products such as coronary balloons and coronary guide wires that are matched with the coronary stents have also entered Jiangsu centralized procurement.
    Among them, coronary balloons have entered Jiangsu centralized procurement for the second time.
    The rate of decrease is as high as 94%, and the maximum rate of decrease of the coronary guide wire and coronary guide catheter is 55% and 50%, respectively
    .
     
    At present, the centralized collection of coronary balloons covers almost all provinces in the country, and the Medical Insurance Bureau also clearly requires full coverage in all provinces within the year
    .
    Judging from the results of the current public negotiations, the price war for coronary balloons has intensified.
    The selected prices in centralized procurement are basically 100 yuan, the highest drop is 96.
    34% of the centralized procurement of the Guangdong 7-province alliance, and the lowest price is 125 yuan/piece
    .

     
      The coronary guide wire and coronary guide catheter are gradually entering other provinces for centralized procurement
    .
    The exhaustion of coronary interventional products is undoubtedly a further consolidation of the results of centralized procurement of coronary stents
    .

     
      As coronary interventional products enter the price reduction vortex one by one, the market size of the cardiovascular field has further shrunk
    .
     
      Cardiac pacemaker short-term "hard big price"
     
      It is the second time that cardiac pacemakers have entered the centralized procurement of Jiangsu Province
    .
    The first average drop was 15.
    86% and the highest drop was 38.
    13%; the second average drop was 60% and the highest drop was 69%.
    From the perspective of the drop, there was a significant increase in the second time
    .

     
      However, compared with other high-value consumables, the price reduction of pacemakers is still relatively limited
    .
    From the perspective of the decline in centralized procurement in various provinces, the average decline in pacemakers is between 15% and 60%, and the companies that have won the bid in centralized procurement are mainly import companies
    .

     
     
      The import monopoly and the small market share of domestic enterprises are the main reasons for the limited decline
    .
     
      In the article "The first domestically-made temporary pacemaker came out, and the process of localization may be "long and long"", the Medical Equipment Hui mentioned that centralized procurement can indeed achieve a certain price reduction, but in the short term, cardiac pacemakers will not Like other products with mature technology and completed domestic substitution, they will face a sharp drop in prices
    .
     
      90% of China's market is still monopolized by import companies such as Medtronic, Poco, Abbott, and Bidorick
    .
    Domestic companies mainly include Lepu Medical, Chuangling Cardiac Rhythm Medical and LifeTech
    .
    At present, domestic production still relies on imported technologies and products for chips, wires, and batteries.
    In the face of technical constraints, localization is still difficult
    .
     
      In addition, the technical barriers of pacemakers are high, and enterprises have high investment in early R&D and high risks.
    If the price of centralized procurement is too low, it will be lethal to enterprises
    .
     
      Therefore, even if it enters the centralized procurement, the inherent price system is difficult to break, and it is still difficult to sharply reduce the price of cardiac pacemakers in the short term
    .
     
      The pattern of intraocular lens is "expected to be reshaped"
     
      Into the centralized procurement of Jiangsu Province again there are artificial lenses
    .
    At present, the centralized procurement of intraocular lenses basically covers the whole country.
    In the centralized procurement of intraocular lenses in Henan Province, the average decline is 56.
    30%, and the highest decline is 85.
    69%
    .
    From the overall statistical data, the overall average drop of intraocular lenses is about 40% or more
    .
     
     
      Although the price reduction of centralized procurement has led to a decline in corporate profits, for domestic intraocular lens companies, centralized procurement is also a good opportunity to accelerate market capture
    .
     
      Taking the domestic brand Aibo Nuo De as an example, in the procurement of intraocular lens belts in Anhui Province , Ai Bo Nuo De's foldable one-piece intraocular lens (proming Pu Nuo Ming) won the bid
    .
    After the collection, the average monthly sales revenue of Aibo Medical's intraocular lens business in Anhui Province from August to December 2019 was 709,600 yuan, an increase of 53.
    61% compared with the average monthly sales revenue from January to July 2019, achieving rapid growth
    .

     
      At present, there are 20 imported brands and 3 domestic brands of intraocular lenses in China.
    Under the environment of import monopoly, the advantages of domestic brands are not obvious, and they are mainly concentrated in the low-end market
    .
    In the future, with the deepening of centralized procurement, artificial crystal companies capable of breaking through technical barriers are expected to obtain more market channel resources through mass procurement, thereby breaking the market situation of import monopoly
    .

      Medical News, June 18, June 15, Jiangsu Medical Insurance Bureau released the latest developments, Jiangsu Province has completed the fifth round of centralized procurement negotiations for medical consumables
    .
     
      It is understood that since Jiangsu took the lead in the procurement of coronary stent belts in 2019, it has successively carried out 5 rounds of medical consumables belt procurement, involving a total of 2,426 products in cardiovascular, ophthalmology, orthopedics, general surgery and other departments, an average decrease of 54%.

    .
     
      Five rounds of medical consumables and tape purchase decline in Jiangsu Province
     
      This round of centralized procurement involves 5 types of medical consumables, including intraocular lenses, coronary dilatation balloons, dual-chamber pacemakers, coronary guide wires, and coronary guide catheters
    .
    Among them, intraocular lenses, coronary balloons, and pacemakers have experienced the baptism of centralized procurement in Jiangsu Province in 2019
    .
    From the perspective of price reduction, the decline of "secondary centralized procurement" products has increased significantly, and the highest decline of coronary balloons is as high as 94%
    .
     
      Coronary interventional products "all in one catch"
     
      With the implementation of the results of the national procurement of coronary stents, products such as coronary balloons and coronary guide wires that are matched with the coronary stents have also entered Jiangsu centralized procurement.
    Among them, coronary balloons have entered Jiangsu centralized procurement for the second time.
    The rate of decrease is as high as 94%, and the maximum rate of decrease of the coronary guide wire and coronary guide catheter is 55% and 50%, respectively
    .
     
      At present, the centralized collection of coronary balloons covers almost all provinces in the country, and the Medical Insurance Bureau also clearly requires full coverage in all provinces within the year
    .
    Judging from the results of the current public negotiations, the price war for coronary balloons has intensified.
    The selected prices in centralized procurement are basically 100 yuan, the highest drop is 96.
    34% of the centralized procurement of the Guangdong 7-province alliance, and the lowest price is 125 yuan/piece
    .

     
      The coronary guide wire and coronary guide catheter are gradually entering other provinces for centralized procurement
    .
    The exhaustion of coronary interventional products is undoubtedly a further consolidation of the results of centralized procurement of coronary stents
    .

     
      As coronary interventional products enter the price reduction vortex one by one, the market size of the cardiovascular field has further shrunk
    .
     
      Cardiac pacemaker short-term "hard big price"
     
      It is the second time that cardiac pacemakers have entered the centralized procurement of Jiangsu Province
    .
    The first average drop was 15.
    86% and the highest drop was 38.
    13%; the second average drop was 60% and the highest drop was 69%.
    From the perspective of the drop, there was a significant increase in the second time
    .

     
      However, compared with other high-value consumables, the price reduction of pacemakers is still relatively limited
    .
    From the perspective of the decline in centralized procurement in various provinces, the average decline in pacemakers is between 15% and 60%, and the companies that have won the bid in centralized procurement are mainly import companies
    .

     
     
      The import monopoly and the small market share of domestic enterprises are the main reasons for the limited decline
    .
     
      In the article "The first domestically-made temporary pacemaker came out, and the process of localization may be "long and long"", the Medical Equipment Hui mentioned that centralized procurement can indeed achieve a certain price reduction, but in the short term, cardiac pacemakers will not Like other products with mature technology and completed domestic substitution, they will face a sharp drop in prices
    .
     
      90% of China's market is still monopolized by import companies such as Medtronic, Poco, Abbott, and Bidorick
    .
    Domestic companies mainly include Lepu Medical, Chuangling Cardiac Rhythm Medical and LifeTech
    .
    At present, domestic production still relies on imported technologies and products for chips, wires, and batteries.
    In the face of technical constraints, localization is still difficult
    .
     
      In addition, the technical barriers of pacemakers are high, and enterprises have high investment in early R&D and high risks.
    If the price of centralized procurement is too low, it will be lethal to enterprises
    .
     
      Therefore, even if it enters the centralized procurement, the inherent price system is difficult to break, and it is still difficult to sharply reduce the price of cardiac pacemakers in the short term
    .
     
      The pattern of intraocular lens is "expected to be reshaped"
     
      Into the centralized procurement of Jiangsu Province again there are artificial lenses
    .
    At present, the centralized procurement of intraocular lenses basically covers the whole country.
    In the centralized procurement of intraocular lenses in Henan Province, the average decline is 56.
    30%, and the highest decline is 85.
    69%
    .
    From the overall statistical data, the overall average drop of intraocular lenses is about 40% or more
    .
     
     
      Although the price reduction of centralized procurement has led to a decline in corporate profits, for domestic intraocular lens companies, centralized procurement is also a good opportunity to accelerate market capture
    .
     
      Taking the domestic brand Aibo Nuo De as an example, in the procurement of intraocular lens belts in Anhui Province , Ai Bo Nuo De's foldable one-piece intraocular lens (proming Pu Nuo Ming) won the bid
    .
    After the collection, the average monthly sales revenue of Aibo Medical's intraocular lens business in Anhui Province from August to December 2019 was 709,600 yuan, an increase of 53.
    61% compared with the average monthly sales revenue from January to July 2019, achieving rapid growth
    .

     
      At present, there are 20 imported brands and 3 domestic brands of intraocular lenses in China.
    Under the environment of import monopoly, the advantages of domestic brands are not obvious, and they are mainly concentrated in the low-end market
    .
    In the future, with the deepening of centralized procurement, artificial crystal companies capable of breaking through technical barriers are expected to obtain more market channel resources through mass procurement, thereby breaking the market situation of import monopoly
    .

      Medical News, June 18, June 15, Jiangsu Medical Insurance Bureau released the latest developments, Jiangsu Province has completed the fifth round of centralized procurement negotiations for medical consumables
    .
     
      It is understood that since Jiangsu took the lead in the procurement of coronary stent belts in 2019, it has successively carried out 5 rounds of medical consumables belt procurement, involving a total of 2,426 products in cardiovascular, ophthalmology, orthopedics, general surgery and other departments, an average decrease of 54%.

    .
     
      Five rounds of medical consumables and tape purchase decline in Jiangsu Province
     
      This round of centralized procurement involves 5 types of medical consumables, including intraocular lenses, coronary dilatation balloons, dual-chamber pacemakers, coronary guide wires, and coronary guide catheters
    .
    Among them, intraocular lenses, coronary balloons, and pacemakers have experienced the baptism of centralized procurement in Jiangsu Province in 2019
    .
    From the perspective of price reduction, the decline of "secondary centralized procurement" products has increased significantly, and the highest decline of coronary balloons is as high as 94%
    .
     
      Coronary interventional products "all in one catch"
      Coronary interventional products "all in one catch"
     
      With the implementation of the results of the national procurement of coronary stents, products such as coronary balloons and coronary guide wires that are matched with the coronary stents have also entered Jiangsu centralized procurement.
    Among them, coronary balloons have entered Jiangsu centralized procurement for the second time.
    The rate of decrease is as high as 94%, and the maximum rate of decrease of the coronary guide wire and coronary guide catheter is 55% and 50%, respectively
    .
     
      At present, the centralized collection of coronary balloons covers almost all provinces in the country, and the Medical Insurance Bureau also clearly requires full coverage in all provinces within the year
    .
    Judging from the results of the current public negotiations, the price war for coronary balloons has intensified.
    The selected prices in centralized procurement are basically 100 yuan, the highest drop is 96.
    34% of the centralized procurement of the Guangdong 7-province alliance, and the lowest price is 125 yuan/piece
    .

     
      The coronary guide wire and coronary guide catheter are gradually entering other provinces for centralized procurement
    .
    The exhaustion of coronary interventional products is undoubtedly a further consolidation of the results of centralized procurement of coronary stents
    .

     
      As coronary interventional products enter the price reduction vortex one by one, the market size of the cardiovascular field has further shrunk
    .
     
      Cardiac pacemaker short-term "hard big price"
      Heart heart heartpacemaker short-term "hard big price"
     
      It is the second time that cardiac pacemakers have entered the centralized procurement of Jiangsu Province
    .
    The first average drop was 15.
    86% and the highest drop was 38.
    13%; the second average drop was 60% and the highest drop was 69%.
    From the perspective of the drop, there was a significant increase in the second time
    .

     
      However, compared with other high-value consumables, the price reduction of pacemakers is still relatively limited
    .
    From the perspective of the decline in centralized procurement in various provinces, the average decline in pacemakers is between 15% and 60%, and the companies that have won the bid in centralized procurement are mainly import companies
    .

     
     
      The import monopoly and the small market share of domestic enterprises are the main reasons for the limited decline
    .
     
      In the article "The first domestically-made temporary pacemaker came out, and the process of localization may be "long and long"", the Medical Equipment Hui mentioned that centralized procurement can indeed achieve a certain price reduction, but in the short term, cardiac pacemakers will not Like other products with mature technology and completed domestic substitution, they will face a sharp drop in prices
    .
     
      90% of China's market is still monopolized by import companies such as Medtronic, Poco, Abbott, and Bidorick
    .
    Domestic companies mainly include Lepu Medical, Chuangling Cardiac Rhythm Medical and LifeTech
    .
    At present, domestic production still relies on imported technologies and products for chips, wires, and batteries.
    In the face of technical constraints, localization is still difficult
    .
     
      In addition, the technical barriers of pacemakers are high, and enterprises have high investment in early R&D and high risks.
    If the price of centralized procurement is too low, it will be lethal to enterprises
    .
     
      Therefore, even if it enters the centralized procurement, the inherent price system is difficult to break, and it is still difficult to sharply reduce the price of cardiac pacemakers in the short term
    .
     
      The pattern of intraocular lens is "expected to be reshaped"
      The pattern of intraocular lens is "expected to be reshaped"
     
      Into the centralized procurement of Jiangsu Province again there are artificial lenses
    .
    At present, the centralized procurement of intraocular lenses basically covers the whole country.
    In the centralized procurement of intraocular lenses in Henan Province, the average decline is 56.
    30%, and the highest decline is 85.
    69%
    .
    From the overall statistical data, the overall average drop of intraocular lenses is about 40% or more
    .
     
     
      Although the price reduction of centralized procurement has led to a decline in corporate profits, for domestic intraocular lens companies, centralized procurement is also a good opportunity to accelerate market capture
    .
    Enterprise business enterprise
     
      Taking the domestic brand Aibo Nuo De as an example, in the procurement of intraocular lens belts in Anhui Province , Ai Bo Nuo De's foldable one-piece intraocular lens (proming Pu Nuo Ming) won the bid
    .
    After the collection, the average monthly sales revenue of Aibo Medical's intraocular lens business in Anhui Province from August to December 2019 was 709,600 yuan, an increase of 53.
    61% compared with the average monthly sales revenue from January to July 2019, achieving rapid growth
    .

    Procurement Purchasing Procurement
     
      At present, there are 20 imported brands and 3 domestic brands of intraocular lenses in China.
    Under the environment of import monopoly, the advantages of domestic brands are not obvious, and they are mainly concentrated in the low-end market
    .
    In the future, with the deepening of centralized procurement, artificial crystal companies capable of breaking through technical barriers are expected to obtain more market channel resources through mass procurement, thereby breaking the market situation of import monopoly
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.